Twin Tree Management’s Blueprint Medicines BPMC Stock Holding History

Twin Tree Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-17,028	Closed	-$1.66M	–	1572
2024 Q4	$1.49M	Buy	17,028 +5,074	+42%	+$465K	﹤0.01%	1212
2024 Q3	$1.11M	Buy	+11,954	New	+$1.19M	﹤0.01%	1218
2024 Q2	–	Sell	-5,406	Closed	-$541K	–	1361
2024 Q1	$513K	Buy	5,406 +844	+19%	+$72.4K	﹤0.01%	1106
2023 Q4	$421K	Buy	+4,562	New	+$296K	﹤0.01%	1211
2021 Q4	–	Sell	-1,460	Closed	-$150K	–	1597
2021 Q3	$150K	Buy	+1,460	New	+$136K	﹤0.01%	1415

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Twin Tree Management's BPMC Position: Q1 2025 in Review

Twin Tree Management sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 17,028 shares — an estimated $1.66M sold.

Twin Tree Management first reported a position in BPMC in Q3 2021 and held it in 5 quarters. The position peaked at $1.49M in Q4 2024. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

Twin Tree Management reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
Twin Tree Management sold 17,028 Blueprint Medicines shares in Q1 2025, an estimated $1.66M.
Twin Tree Management first reported a position in Blueprint Medicines in Q3 2021 and held it in 5 quarters.
Twin Tree Management's Blueprint Medicines position peaked at $1.49M in Q4 2024.
352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Twin Tree Management's 13F filing for Q1 2025, filed 15 May 2025.